Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions

A M Minnis, N S Padian

Objective: To evaluate evidence for the effectiveness of female controlled physical and chemical barrier methods in preventing STI/HIV transmission, to examine recent reviews on microbicide development, and to highlight promising research directions. To discuss challenges in conducting effectiveness research and in translating results to public health intervention.

Methods: Systematic review of articles that examined the disease prevention effectiveness of at least one female controlled barrier method. Review of conference abstracts that presented clinical and preclinical microbicide data.

Results: Randomised controlled trials provide evidence that female condoms confer as much protection from STIs as male condoms. Observational studies suggest that the diaphragm protects against STI pathogens. Several microbicide effectiveness studies are under way and new directions, such as adaptation of therapeutic agents as preventive products, are being examined. Substantial attention is now given to product formulation and novel delivery strategies. Combining microbicide products with different mechanisms of action as well as combining chemical and physical barriers will be necessary to maximise prevention effectiveness.

Conclusions: Increased investment in the development and identification of female controlled barrier methods offers promise that additional products will be available in the years ahead. Generalising trial results to a community setting, promoting products that may be less effective than male condoms, and bringing an effective product to scale introduce public health challenges that warrant attention. The need for female controlled barrier methods that provide women with the opportunity to take an active role in reducing their STI/HIV risk are urgently needed and constitute an essential tool to prevent continued spread of these infections.
in combination: HIV; sexually transmitted diseases; contraceptive devices, female; disease prevention; female controlled methods; female condom; cervical cap; diaphragm; microbicides; topical microbicide; efficacy; and effectiveness. We reviewed all articles published in peer reviewed journals that examined the disease prevention effectiveness of at least one female controlled barrier method, regardless of the design and study population. In addition, we examined review papers on this topic and relevant conference abstracts. To supplement the microbicide assessment, we reviewed materials included on the Alliance for Microbicide Development website and the abstracts and presentations from the Microbicides 2002 and 2004 conferences.

PHYSICAL BARRIER METHODS
Female condoms
Laboratory and epidemiological studies have demonstrated that polyurethane female condoms offer protection against STI pathogens, and that protection probably matches that conferred by male condoms.8 Since its introduction, numerous investigations have examined female condom acceptability and use; however, only four published studies have assessed directly the effectiveness of female condoms in preventing STIs.7 Soper et al assessed trichomoniasis re-infection and found that none of the women who used the female condom during each act of sexual intercourse were re-infected 45 days after treatment.9 Though this finding offers compelling evidence of a protective effect of the female condom, the sample was small and the period of follow up was short. Women were given female condoms to use only if they thought they could be compliant users. A dose-response relation of the female condom’s effect on trichomoniasis re-infection among the inconsistent users substantiates the conclusion that the female condom offered a protective effect.

Three studies used a randomised controlled design to evaluate female condom effectiveness and they suggest that the availability and use of female condoms offer at least as much protection from STIs as male condoms alone (see table 1). Fontanet et al randomised sex establishments in Thailand to a male condom only arm or to a male and female condom arm.6 A statistically significant reduction was demonstrated in only one of the four cities but, at all sites, female condoms were at least as effective as male condoms. French et al developed a condom intervention among female clients at public STD clinics in Philadelphia and randomised women either to a female or male condom arm.10 They detected no statistically significant difference in STI prevalence between arms, though the direction of the odds ratio suggested that female condom availability might confer greater STI protection.11 None the less, several limitations should be noted, including assessment of incident STIs through medical record abstraction (50% of women did not have prospective test results) and availability of condom use data for a subsample of females only.

A community randomised trial conducted by Feldblum et al in six matched pairs of Kenyan plantations was designed to examine the additional effect on STI prevalence of the availability of female condoms as part of a prevention programme that included male condom distribution, individual counselling, group meetings, and video and folk presentations.11 Over 1 year, STI prevalence did not vary between the two arms. Qualitative interviews indicated that the female condom was not accepted or promoted consistently by those clinic based providers who participated in both delivery of the intervention and data collection, which probably contributed to an inability to determine an additional effect of the female condom.11

Female condom re-use
Though the female condom is approved as a single use product, reports of re-use of the device have been noted.12 To examine the safety of re-use, the World Health Organization convened a consultation in January 2002.13 They concluded that, though use of a new female condom during each act of intercourse should be recommended, female condoms can be re-used, with careful attention to a disinfection (1:20 dilution of household bleach), washing, drying and re-lubrication procedure. Research on the integrity of female condom re-use to date primarily has been laboratory based,14–16 and suggests that the integrity of the female condom is maintained for at least five uses (if the disinfection recommendations are followed).16 Additional research that examines the STI/HIV prevention effectiveness of female condom re-use through population based studies is needed to inform policy recommendations.

Cervical barriers
The cervix constitutes a primary site of entry for STIs and HIV.17 Simian immunodeficiency virus (SIV)/macaque models18 and a study of HIV acquisition in women with hysterectomies19 demonstrate that HIV can be acquired vaginally; expression of CD4 cells and CCR5 chemokine receptors is higher in the cervix than the vagina.20 The cervical columnar epithelium is thinner than vaginal epithelium, making it more fragile, particularly among oral contraceptive users and during adolescence when ectopy is common.21 Thus, barriers that protect the cervix are

---

**Table 1** Epidemiological evidence for the STI prevention effectiveness of female condoms

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Study population</th>
<th>No</th>
<th>Design</th>
<th>Outcomes</th>
<th>Key findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Soper et al</td>
<td>1993</td>
<td>Gynaecology clinic patients with trichomoniasis (United States)</td>
<td>104</td>
<td>Prospective cohort</td>
<td>Trichomonias</td>
<td>No compliant female condom users re-infected v 14% of women not given female condoms and 14.7% of non-compliant users (p = 0.08)</td>
</tr>
<tr>
<td>Fontanet et al</td>
<td>1998</td>
<td>Sex workers in commercial sex establishments (Thailand)</td>
<td>548</td>
<td>Randomised controlled trial</td>
<td>Chlamydia, gonorrhoea, trichomoniasis, genital ulcer disease</td>
<td>Any STI: RR = 0.76 (95% CI: 0.50 to 1.16) Reduction in STIs in 1 of 4 sites: RR = 0.47 (95% CI: 0.25 to 0.91)</td>
</tr>
<tr>
<td>Feldblum et al</td>
<td>2001</td>
<td>Women in six matched community pairs (Kenya)</td>
<td>1752</td>
<td>Community randomised controlled trial</td>
<td>Chlamydia, gonorrhoea, trichomoniasis</td>
<td>Any STI: OR = 1.1 (95% CI: 0.8 to 1.6)</td>
</tr>
<tr>
<td>French et al</td>
<td>2003</td>
<td>Women seen at STD clinic (United States)</td>
<td>1442</td>
<td>Randomised controlled trial</td>
<td>Chlamydia, gonorrhoea, trichomoniasis, syphilis</td>
<td>Any STI, comparing female vs male condoms to male condom alone: RR = 0.79 (95% CI: 0.59 to 1.06)</td>
</tr>
</tbody>
</table>

---

www.stijournal.com
considered strong HIV prevention candidates. To date, all studies of diaphragm STI prevention effectiveness have been observational, and several are limited by their consideration of multiple barrier methods simultaneously. Currently, several diaphragm effectiveness randomised controlled trials are under way, including a study in Zimbabwe and South Africa of its HIV prevention effectiveness, and a study of its STI prevention effectiveness in Kenya. A recent review concluded that observational studies offer evidence that the diaphragm protects against STI pathogens, including gonorrhoea, pelvic inflammatory disease (PID), tubal infertility, and cervical dysplasia. These data are summarised in table 2 and were described by Moench et al. There are several limitations to these data. Firstly, all the studies were either cross sectional or case-control in design and only considered "current method use" as their primary measure of method use. Secondly, diaphragm users may have a lower risk profile than non-diaphragm users. Indeed, in the study by Rosenberg et al, the prevalence of trichomoniasis, a non-cervical infection, was also lower among diaphragm users. Similarly, in the study by Wright et al, diaphragm users had a later age of first sexual intercourse than did pill or intrauterine device (IUD) users. Thirdly, the comparison groups varied and consisted of either women using non-barrier methods or not using contraception. These two groups may be distinct in their use of health care, socioeconomic status, and in level of sexual activity or other behavioural practices that increase risk for STIs and would probably influence the observed measures of association. Finally, the simultaneous use of nonoxynol-9 (N-9) containing spermicidal gel with the diaphragm may have influenced the observed STI prevention effectiveness. The results from the ongoing diaphragm effectiveness trials will offer more definitive answers about the role of the diaphragm in HIV and STI prevention.

CHEMICAL BARRIERS

The ideal microbicide should prevent HIV and STIs without disrupting the vaginal or rectal mucosa, be effective for vaginal and rectal use for a wide range of STIs and HIV viral clades, offer contraceptive properties, retain local rather than systemic effects, and be affordable and resilient to transport and temperature. The approaches adopted for microbicide development are typically classified by their mechanism of action (table 3).

A recent review concluded that observational studies offer evidence that the diaphragm protects against STI pathogens, including gonorrhoea, pelvic inflammatory disease (PID), tubal infertility, and cervical dysplasia. These data are summarised in table 2 and were described by Moench et al. There are several limitations to these data. Firstly, all the studies were either cross sectional or case-control in design and only considered "current method use" as their primary measure of method use. Secondly, diaphragm users may have a lower risk profile than non-diaphragm users. Indeed, in the study by Rosenberg et al, the prevalence of trichomoniasis, a non-cervical infection, was also lower among diaphragm users. Similarly, in the study by Wright et al, diaphragm users had a later age of first sexual intercourse than did pill or intrauterine device (IUD) users. Thirdly, the comparison groups varied and consisted of either women using non-barrier methods or not using contraception. These two groups may be distinct in their use of health care, socioeconomic status, and in level of sexual activity or other behavioural practices that increase risk for STIs and would probably influence the observed measures of association. Finally, the simultaneous use of nonoxynol-9 (N-9) containing spermicidal gel with the diaphragm may have influenced the observed STI prevention effectiveness. The results from the ongoing diaphragm effectiveness trials will offer more definitive answers about the role of the diaphragm in HIV and STI prevention.

CHEMICAL BARRIERS

The ideal microbicide should prevent HIV and STIs without disrupting the vaginal or rectal mucosa, be effective for vaginal and rectal use for a wide range of STIs and HIV viral clades, offer contraceptive properties, retain local rather than systemic effects, and be affordable and resilient to transport and temperature. The approaches adopted for microbicide development are typically classified by their mechanism of action (table 3).

Several reviews of the state of microbicide development have been published recently. One, by Keller et al, focused specifically on preclinical development. They argued for testing microbicides in primary culture systems versus cell lines and used N-9 as an example of primary culture system research that pointed to adverse consequences not detected in cell lines. Harrison et al presented an update on microbicide development and highlighted several clinical research challenges. One relates to the difficulty of evaluating the potential efficacy of candidate products owing to the lack of available surrogate end points. Traditionally, phase II safety trials are designed to include evaluation of potential efficacy ("proof of concept"). But, in microbicide research, there are no accepted surrogate end points for HIV that can be assessed in these smaller studies. Other STIs have been used to demonstrate biological plausibility for microbicide products with general mechanisms of action, such as strengthening the natural vaginal defences (both in vitro and in phase II trials). In expanded phase I studies, examination of effects of candidate products on the genital tract immune microenvironment (for example, innate immunological factors, immune
cell populations), alterations which influence acquisition of STIs, could facilitate early clinical screening of products. Anticipating product effectiveness from adverse safety outcomes (limited local toxicity, evidence of damage to vaginal and cervical epithelium) remains challenging, as the degree to which microbicide toxicity alters HIV/STI susceptibility may not be measured well by current techniques, and the clinical significance of abnormal findings is sometimes difficult to establish. A need exists for more sensitive indicators of microbicide induced inflammatory responses that could increase HIV/STI susceptibility and infectiousness. Though the majority of microbicide products are currently in preclinical development, 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials. Furthest along in the development pipeline, either because they are already in phase II/IIb trials or phase III (effectiveness) trials, or are in preclinical development, 36 18 products are being evaluated now in clinical research studies, most in small phase I safety and acceptability trials.
Female controlled barrier method effectiveness

and delivery; (2) development of products either for rectal use, specifically, or that are suitable for both the genital and gastrointestinal tracts; and (3) the development of combination products—both to inactivate the HIV virus using several approaches and to inhibit several STI pathogens simultaneously.

Critical issues related to product formulation and delivery include product coverage of the vaginal area, application method, dosage, volume, and concerns regarding systemic effects of a product that is absorbed and/or ascends the reproductive tract. Formulation and volume greatly affect product diffusion. Barnhard et al have developed strategies for examining product diffusion using magnetic resonance imaging.41 Product acceptability, frequency of product use, and frequency of coital activity are linked closely with each of these issues. One particular challenge with vaginal delivery of microbicide products has been the need to provide a sufficiently high dose that offers protection for multiple hours and/or sexual acts. Malcolm et al have adapted the contraceptive intravaginal ring as a potential microbicidal delivery device (using N-9 and, more recently, dextran sulfate,42 as models), which, through a more controlled delivery device (using N-9 and, more recently, dextran contraceptive intravaginal ring as a potential microbicide) hours and/or sexual acts. Malcolm et al.13,43,44,45 A controlled release delivery system could not only reduce adverse effects on vaginal epithelium and, potentially, systemic effects, but also improve user acceptability. Nucleotide reverse transcriptase inhibitors may be most compatible with rings because of their molecular weight.44 Devices capable of releasing larger molecular weight products have been developed. For example, in a mouse model, vaginal discs that released antibody to HSV-2, demonstrated protection from HSV-2 infection. Intravaginal devices could be designed as compartmentalised to accommodate multiple microbicidal products.44 Other innovative microbicidal delivery systems that are genetic modification of native vaginal lactobacilli to deliver anti-HIV products46 and penile wipes.47 Combination microbicides might block transmission at multiple points in the infection process (for example, disrupt the viral envelope and prevent replication of infected cells using antiviral therapy); act at different tissue sites (for example, epithelium, lymph node); and provide protection against multiple infections that are known to increase risk for HIV through their disruption of protective epithelial surfaces. Furthermore, a combination microbicidal product may minimise resistance that may develop towards products designed to initiate specific cellular activity and expand product effectiveness across multiple viral clades. Though physical and chemical barriers primarily have been developed independently of each other, the combination of cervical barriers and microbicides offers a compelling approach to STI and HIV prevention. The BufferGel cap, for example, is being developed as a cervical barrier for delivery of BufferGel microbicidal. An expanded phase 1 safety study of Instead Softcup (a disposable diaphragm) and AcidForm gel is planned for South Africa (M Callahan, personal communication, 23 August 2004).

METHODOLOGICAL CONTROVERSIES IN STUDY DESIGN

The most rigorous and efficient design for phase III effectiveness trials of microbicide products and physical
barrier methods remains controversial. Owing to ethical obligations to provide study participants with the most effective prevention methods available—currently, male condoms and counselling in their use—only the marginal effectiveness of providing an additional product can be assessed in an effectiveness trial.64 This, clearly, requires a larger study, which adds complexity and expense.

The US Food and Drug Administration has announced that initial evaluations of microbicide products should include two control arms: a placebo and a condom only arm.52 Given the added expense and time required to recruit, enrol and follow additional participants for regular behavioural and biological assessments, the utility of including two control arms has been debated by Stein et al and by Padian.54–57 The placebo product (plus condom) arm retains the double blinded feature of the randomised controlled trial, which permits direct assessment of the experimental product, unbiased by differences in behaviour and study retention. Furthermore, it provides opportunity for assessment of whether the active product offers disease prevention properties above and beyond lubrication effects. Developing and/or identifying a placebo product that lacks antimicrobial activity is challenging and, as demonstrated in the COL-1492 trial of nonoynol-9,58 a placebo product may also offer protective properties that minimise the ability to detect an effect of the active product being evaluated. In addition, placebos can modify the immune activation status of the reproductive tract, and evidence suggests that some placebos planned for use may have HIV activity that offers unintended protection.59 Thus, a condom only arm allows assessment of the protective effect of the placebo, which may be essential. Much progress has been made in developing an inert placebo product, with HEC (hydroxyethylcellulose) now available for effectiveness trials.60

In light of the urgency with which an effective microbicide product is needed, conducting efficient trials that maintain the highest scientific rigor remains important. Two strategies that could reduce the size, time, and cost of the phase III effectiveness trials are use of surrogate biological markers for HIV as the study end points and expanded use of phase IIb safety/limited effectiveness studies.61–63 If an STI with higher incidence is used, such as herpes simplex virus 2 (HSV-2) or another immunological marker of STI and/or HIV susceptibility, the power to detect an effect would remain high with fewer participants followed for shorter periods of time. Through mathematical modelling of behavioural strategies for STI and HIV risk reduction, Pinkerton et al demonstrated that the appropriateness of a particular STI biomarker for HIV depends on how closely its infectivity reflects that of HIV.64 A smaller, phase IIb “screening” study, that includes an initial focus on safety and permits identification of a highly effective product (and, similarly, a rejection of a highly ineffective product), has been proposed as an alternative to moving directly from safety and acceptability investigations to a phase III effectiveness trial. This design is appealing as it offers a more efficient and cost effective strategy for screening out promising products that prove ineffective.

**Alternative measures of effectiveness for STIs and HIV**

Examination of semen exposure, through tests such as prostate specific antigen (PSA), represents a novel measure of physical barrier method effectiveness employed in several recent studies.65–69 PSA tests detect relatively small amounts of semen, and, given the unknown infectious dose of the STI and HIV organisms, the consequences of these exposures to semen is unknown. Interpreting the public health significance of PSA levels requires additional research on what level of PSA exposure in semen is meaningful for disease transmission, and, given natural variation of PSA concentration in semen, what level of semen exposure indicates method failure.

**TRANSLATING EFFECTIVENESS RESULTS TO PUBLIC HEALTH INTERVENTION**

Translating results of effectiveness studies to public health intervention includes consideration of several issues. The first relates to generalising results from a trial to real use settings. In the context of a study trial, participants may use the study product(s) more frequently than individuals who are not in a trial, for reasons that include a sense of obligation to the research staff because they are being financially compensated for their participation, because they are receiving healthcare services through the trial, and because, by signing a consent form, they agreed to participate and use the study product(s) they are given. In addition, regular study visits, during which participants are asked questions about their method use frequency and are counselled on strategies for successful use of the products, may function as an intervention that promotes method use or changes in high risk behaviours. Furthermore, owing to trial eligibility criteria, participants may be healthier, more compliant, or otherwise different from those who ultimately use the product. In generalising study results, then, the population effect of the product may be overestimated because in a real use setting the consistency of product use may be lower than that achieved in the effectiveness trial.

**Condom migration**

Much attention has been given to the issue of condom migration—that is, movement away from condoms towards a less effective device or product. This may occur in studies if women in the product arm had been consistent condom users but are not because the study product is now available to them. Examinations of this phenomenon, however, suggest that condom migration generally does not present a great public health dilemma. The female condom effectiveness study by Fontanet et al suggested that the availability of both male and female condoms did not influence the total proportion of protected acts, but may have reduced the proportion that were protected by male condoms.66 Foss et al presented a summary of the condom migration evidence from studies that offered condoms and spermicides and concluded that six of the nine studies found that the expanded method options increased condom use and only in the remaining three did condom use decrease.67 They also included a model using data from Cotonou, Benin, to examine the hypothetical effects on HIV prevention of introducing a microbicide with 50% HIV and STI prevention efficacy, assuming 10% condom migration. The model suggested that migration from condom use would only begin to increase risk among groups with initial condom use consistency greater than 70% and microbicide use lower than 50% for acts that were not protected by condoms. An examination of condom migration in a diaphragm acceptability study demonstrated that male condom use, with or without simultaneous use of a diaphragm, did not decrease over a 6 month period following introduction of the diaphragm.68 Thus, while some condom migration may occur, in general it does not appear to lead to a greater proportion of unprotected acts.

**Risk compensation**

Risk compensation, or an increase in risky behaviours as a result of an anticipated protective effect of an intervention, constitutes another potential public health issue. Indeed, this has been cited as a caution against the promotion of male condoms, particularly because of their varying levels of effectiveness across STI pathogens.69 The hypothesis is that
individuals accept a certain level of risk and that shifts in risk tolerance occur in the face of additional protection. For example, in the area of public health safety and injury prevention, the introduction of safety devices such as seat belts, helmets, and anti-lock brakes initiated concern that individuals would increase their driving speed and recklessness.\(^7\) A study of risk compensation among recipients of post-exposure prophylaxis (PEP) for potential sexual exposure to HIV found that individuals who received PEP did not increase their practice of risky sexual behaviours over the next year.\(^7\) The availability and promotion of microbicides and other cervical barriers may indeed prompt an increase in behavioural risks; however, no strong evidence exists that the promotion of male condoms, which may also prompt similar behavioural changes, has led to increased STI/HIV risk.

**Manufacturing and access**

Finally, ensuring the ability to manufacture a low cost product and/or device found to be effective in preventing HIV and STIs necessitates guidance from commercial manufacturers early on in product development. Consideration of strategies for a stepwise introduction that includes plans for which regions and population groups to target, how to educate providers and potential users, timeframe, ability to produce the product locally or regionally, and financing and licensing procedures are essential. Ideally, planning and advocacy on many of these issues will position the public health community to minimise delay between the identification of an effective product and its dissemination to communities at greatest risk for HIV infection.

**CONCLUSION**

With substantial public and private investment in the field of female controlled methods for HIV and STI prevention, we should expect tremendous advancement in the years ahead. It is anticipated that initial microbicides and cervical barriers may not be as effective as male condoms, but they will provide women with the opportunity to take an active role in reducing their risk without requiring partner negotiation during intercourse. Six microbicide products are currently being evaluated for effectiveness and numerous products are in the development pipeline. However, the objective of identifying effective female controlled methods should not obscure the ultimate goal of addressing vulnerability and gender inequities through gains in women’s economic independence, educational attainment, and cultural shifts in gender based violence. Indeed, such changes may be required to facilitate use of female controlled methods by women who are most at risk for HIV infection, as these women may be most likely to believe their partner’s cooperation is required, even for a method that is seemingly or, in fact, controlled by them. None the less, even if these long term and socially sustainable goals could be achieved, the mandate for female controlled barrier methods will remain an essential tool to prevent continued spread of the STI/HIV epidemics.

**ACKNOWLEDGEMENTS**

We thank Dr Ian McGowan at the David Geffen School of Medicine at the University of California Los Angeles for providing a summary on the status of rectal microbicide development for this manuscript. In addition, thanks are extended to Dr Ariane van der Strat ten for her review of an early version of the manuscript, to Joelle Brown for her contribution to review and synthesis of material presented at the Microbicides 2004 conference, and to Dr Kevin Whaley for his review and thoughtful suggestions for the manuscript.

**CONTRIBUTORS**

AM assumed primary responsibility for developing the manuscript, including defining its structure, reviewing the effectiveness literature and methodological challenges, and writing the text. NP provided input in all of these areas, particularly in outlining the scope of the review and in editing the text.